Newsletter comparison
Dr. Jessica Knurick vs Dr. Noc, PhD
Short answer: Choose Jessica Knurick for a recurring health-policy and safety roundup. Choose Dr. Noc for a focused check on a viral claim. Keep both when the policy development and the misinformation around it need separate treatment.[1][2][3][4][5][6]
An independent guide. Scottie isn't affiliated with, endorsed by, or sponsored by Dr. Jessica Knurick and Dr. Noc, PhD. Each publication owns its name, writing, and subscription terms.
A brief from both newsletters · July 31, 2026
See both newsletters in one brief
See what made the brief, what didn't, and the original links behind every included story.
In this brief: Scottie kept the selected stories separate because they added different value.
Reader priorities
A reader wants health-policy updates and fast correction of viral medical claims before acting on them or passing them along.
These are illustrative priorities, not a customer’s data.
What made the brief
- Dr. Jessica Knurick1 read · 1 included
- Dr. Noc, PhD3 read · 2 included
Scottie
Scottie example brief
July 31, 2026 · Executive brief
01 / The rundown
- An FDA advisory panel recommended easing compounding rules on six unproven peptides, sparking viral misclaims that the agency approved the injections.
- New p-tau217 blood tests boost diagnostic accuracy for patients with memory loss, but experts urge asymptomatic adults to skip direct-to-consumer screens.
- Federal lawmakers introduced the MediKids Act to provide universal healthcare for Americans under 26, though congressional passage remains unlikely.
02 / The briefing
01 / main
FDA panel backs easier access to minimally tested peptides
The takeaway: An FDA advisory committee voted to ease compounding restrictions on six minimally tested peptides despite warnings from agency scientists about tumor growth risks. Contrary to viral online claims, the FDA has not officially approved these injections.
Concrete details
- The committee voted to ease restrictions on six of seven reviewed peptides, including BPC-157 and TB-500.
- Career scientists warned that compounding pharmacies making these products are not required to report adverse safety events.
Why it matters for this reader: You can correct online claims asserting FDA approval; the panel only recommended easing compounding rules, leaving official FDA approval untouched.
Original sourcesDr. Jessica KnurickDr. Noc, PhD
02 / main
Viral Alzheimer's blood tests cannot accurately predict your future
The takeaway: Viral headlines claim new blood tests predict Alzheimer's years early, but the tests are only cleared for patients already displaying memory symptoms. For healthy individuals, guidelines strongly advise against taking them due to misinterpretation risks.
Concrete details
- Primary-care diagnostic accuracy jumped from 65% to 93% when doctors used p-tau217 blood test results for symptomatic patients.
- Direct-to-consumer p-tau tests range from $388 to $900 out of pocket despite official recommendations against asymptomatic screening.
Why it matters for this reader: Next time someone brings up direct-to-consumer Alzheimer's tests, you can explain that these tools only help evaluate people with existing symptoms.
Original sourcesDr. Noc, PhD
03 / main
Proposed MediKids Act targets universal health coverage for youth
The takeaway: Senator Andy Kim introduced the MediKids Act to guarantee free health coverage for every child from birth through age 26. While supported by major medical groups, the bill faces slim odds in the current Congress.
Concrete details
- The bill aims to cover 4.4 million uninsured and 23 million underinsured children currently living in the United States.
- An estimated two million additional children are projected to lose existing Medicaid or CHIP coverage under recent federal cuts.
Why it matters for this reader: Keep this policy proposal on your radar to track how lawmakers attempt to counter recent federal cuts to pediatric health programs.
Original sourcesDr. Jessica Knurick
Action items
- Warn friends buying direct-to-consumer Alzheimer's blood tests that medical guidelines recommend against testing without existing cognitive symptoms.
- Clarify social media posts about peptide regulation by noting the FDA has not approved these compounded injections.
See every issue behind this brief
FDA Panel Eases Restrictions on Peptides
- FDA Committee Backs Peptides, Cyclospora Reaches Record Levels, and a New Bill Proposes Universal Healthcare for KidsDr. Jessica Knurick · Included
Evaluating the '78% Alzheimer's Risk' Blood Test Claims
- The Truth About the "78% Alzheimer's Risk" Blood TestDr. Noc, PhD · Included
FDA Peptide Restrictions
- No, the FDA did not "approve" those peptidesDr. Noc, PhD · Included
Creator Background Introduction
- welcome to the Quack ZoneDr. Noc, PhD · Read, not included
The useful difference
The difference that matters
Jessica Knurick provides a broad, evidence-linked policy and safety briefing. Dr. Noc focuses on specific misinformation, regulatory misstatements, and concise medical explainers.[1][2][3][4][5][6]
What each is best for
Dr. Jessica Knurick
Jessica Knurick contributes current health-policy, FDA, food-safety, environmental-health, and legislative developments with supporting links.[1][2][3]
Dr. Noc, PhD
Dr. Noc contributes concise evidence checks on infectious disease, medical products, and claims that misstate what regulators approved.[4][5][6]
When it’s worth reading both
Scottie can combine the factual regulatory update while retaining the specific correction and the evidence used to make it.[1][2][3][4][5][6]
Sources and official links
- Dr. Jessica Knurick official publication
- Joining the Call for the Immediate Resignation of RFK Jr.
- FDA Committee Backs Peptides, Cyclospora Reaches Record Levels, and a New Bill Proposes Universal Healthcare for Kids
- Dr. Noc, PhD official publication
- Hantavirus: what to know
- No, the FDA did not "approve" those peptides